本文選題：貝伐珠單抗 + 器官穿孔　； 參考：《中國醫(yī)院藥學(xué)雜志》2017年01期

【摘要】：目的:分析貝伐珠單抗致器官穿孔的發(fā)生規(guī)律及特點,為安全用藥提供參考。方法:以"貝伐珠單抗"、"穿孔"為中文關(guān)鍵詞,以"bevacizumab"、"perforation"為英文關(guān)鍵詞,檢索中國學(xué)術(shù)期刊全文數(shù)據(jù)庫、維普中文科技期刊數(shù)據(jù)庫、萬方數(shù)據(jù)庫以及PubMed,收集貝伐珠單抗致器官穿孔個案報道文獻進行分析,檢索時間為2004年2月—2016年3月。結(jié)果:共檢索到貝伐珠單抗致器官穿孔個案報道32篇,涉及41例患者,男23例,女18例,年齡≥65歲的老年患者11例,穿孔多發(fā)生于開始用藥后15周內(nèi)(28例,68.3%)。穿孔部位主要累及胃腸道(26例,63.4%)及鼻中隔(11例,26.8%)�；颊咴技膊≈饕獮檗D(zhuǎn)移性大腸癌(24例,58.5%),貝伐珠單抗聯(lián)合FOLFOX化療(貝伐珠單抗奧沙利鉑+亞葉酸鈣+5-氟尿嘧啶)9例,FOLFIRI(貝伐珠單抗+伊立替康+亞葉酸鈣+5-氟尿嘧啶)6例。有21例患者記錄貝伐珠單抗用藥劑量,其中每次化療給予10 mg·kg-1有13例。貝伐珠單抗致致器官穿孔的臨床癥狀與穿孔部位有關(guān),胃腸道穿孔的臨床表現(xiàn)為主要為腹痛、惡心嘔吐、發(fā)熱等;鼻中隔穿孔臨床表現(xiàn)主要鼻痛,流鼻涕,間歇性鼻出血。結(jié)論:貝伐珠單抗致器官穿孔可能與患者原患疾病、聯(lián)合化療用藥、給藥劑量有關(guān),應(yīng)加強貝伐珠單抗致器官穿孔監(jiān)測,及時發(fā)現(xiàn)和處理器官穿孔。
[Abstract]:Objective: to analyze the occurrence and characteristics of perforation caused by bevacizumab and to provide reference for safe drug use. Methods: using "bevacizumab" and "perforation" as Chinese keywords and "bevacizumab" and "perforation" as English keywords, the full text database of Chinese academic journals and the database of Chinese scientific and technological journals were searched. Wanfang database and PubMed. were collected and analyzed from February 2004 to March 2016 for analysis of the cases of perforation caused by bevacizumab. Results: a total of 32 cases of organ perforation caused by bevacizumab were reported, involving 41 patients (23 males, 18 females, 11 elderly patients aged 鈮，

本文編號：1781187